» Karo Bio Announces Successful Phase II Study With Eprotirome In Combination With Statin
Karo Bio has successfully completed a 12 week phase IIb study of eprotirome (KB2115) given to patients with dyslipidemia (elevated blood lipids). These patients were already on statin treatment. Data…